Scientific area
3.1 Basic medicine
Discipline(s)
Neurosciences (including psychophysiology)
Project title
Eslicarbazepine acetate, Monotherapy
Scientific Coordinator's name:
Prof. Patrício Soares-da-Silva
Scientific Coordinator's e-mail:
psoares.silva@bial.com
Principal R&D Unit:
Prof. Patrício Soares-da-Silva
Other R&D Units involved in the project:
Other R&D units involved in the project
Project keyword(s)
Eslicarbazepine acetate, Epilepsy, Monotherapy
Short abstract and comments
Given the efficacy of eslicarbazepine acetate in controlling partial-onset seizures, the good tolerability and the convenience of QD dosing instead of twice daily (BID) dosing, eslicarbazepine acetate could offer a beneficial alternative as a first-line therapy in patients newly diagnosed with epilepsy experiencing partial-onset seizures. Eslicarbazepine acetate is currently under development by BIAL - Portela & Cª, S.A. for the indication in monotherapy in patients with newly diagnosed partial-onset seizures. Study is being conducted in an estimated 170 centers in approximately 30 countries. This study aims to demonstrate the efficacy and safety of eslicarbazepine acetate as a monotherapy treatment.
Potential uses/indications
Monotherapy
Status
Ongoing
Partner Status: Seeking Partners?
No
Grant number (QREN, FP7, Eureka, etc)
QREN 4859
Last edited on
2011-11-09 14:16:56